Fjarde Ap Fonden Neurocrine Biosciences Inc Transaction History

Fjarde Ap Fonden

$11.6 Billion
Q3 2025

A detailed history of Fjarde Ap Fonden transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Fjarde Ap Fonden holds 37,223 shares of NBIX stock, worth $5.39 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

37,223

Previous 59,123 37.04%

Holding current value

$5.39 Million

Previous $7.43 Million 29.69%

% of portfolio

0.05%

Previous 0.07%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 28, 2025	SELL	$123.98 - $146.67 $2.72 Million - $3.21 Million	-21,900 Reduced 37.04%	37,223 $5.23 Million
Q2 2025 Aug 01, 2025	SELL	$87.54 - $128.18 $744,090 - $1.09 Million	-8,500 Reduced 12.57%	59,123 $7.43 Million
Q1 2025 May 13, 2025	BUY	$107.22 - $153.29 $1.29 Million - $1.84 Million	12,000 Added 21.57%	67,623 $7.48 Million
Q4 2024 Feb 04, 2025	BUY	$111.62 - $139.44 $256,726 - $320,712	2,300 Added 4.31%	55,623 $7.59 Million
Q3 2024 Nov 08, 2024	BUY	$114.58 - $153.15 $1.29 Million - $1.73 Million	11,300 Added 26.89%	53,323 $6.14 Million
Q1 2024 Apr 25, 2024	BUY	$130.4 - $143.74 $456,400 - $503,090	3,500 Added 9.09%	42,023 $5.8 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $655,194 - $820,058	-6,177 Reduced 13.82%	38,523 $5.08 Million
Q3 2023 Oct 23, 2023	BUY	$94.02 - $117.1 $733,356 - $913,380	7,800 Added 21.14%	44,700 $5.03 Million
Q2 2023 Aug 02, 2023	BUY	$89.53 - $104.87 $984,830 - $1.15 Million	11,000 Added 42.47%	36,900 $3.48 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $385,851 - $504,382	4,100 Added 18.81%	25,900 $2.62 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $565,616 - $673,418	-5,300 Reduced 19.56%	21,800 $2.6 Million
Q2 2022 Aug 11, 2022	SELL	$75.79 - $100.07 $90,948 - $120,083	-1,200 Reduced 4.24%	27,100 $2.64 Million
Q1 2022 May 13, 2022	SELL	$72.45 - $94.81 $550,620 - $720,556	-7,600 Reduced 21.17%	28,300 $2.65 Million
Q4 2021 Feb 15, 2022	BUY	$79.65 - $106.22 $127,440 - $169,952	1,600 Added 4.66%	35,900 $3.06 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $241,304 - $277,284	-2,800 Reduced 7.55%	34,300 $3.29 Million
Q2 2021 Aug 12, 2021	BUY	$89.43 - $102.27 $187,803 - $214,767	2,100 Added 6.0%	37,100 $3.61 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $70,056 - $95,520	800 Added 2.34%	35,000 $3.4 Million
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $260,730 - $324,990	3,000 Added 9.62%	34,200 $3.28 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $259,632 - $364,905	2,700 Added 9.47%	31,200 $3 Million
Q2 2020 Aug 13, 2020	SELL	$85.09 - $130.36 $59,563 - $91,252	-700 Reduced 2.4%	28,500 $3.48 Million
Q1 2020 May 11, 2020	SELL	$75.11 - $113.76 $37,555 - $56,880	-500 Reduced 1.68%	29,200 $2.53 Million
Q4 2019 Feb 10, 2020	BUY	$86.8 - $118.57 $2.58 Million - $3.52 Million	29,700 New	29,700 $3.19 Million

Others Institutions Holding NBIX

# of Institutions

724

Shares Held

102M

Call Options Held

230K

Put Options Held

477K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

News

Stay updated on Fjarde Ap Fonden with notifications on news.

Account